Autopsy report · NCT04414514

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

“The PI left the Institution and sponsor decided to close the trial.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 4 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Milton S. Hershey Medical Center

Sponsor type

University, hospital or other

Conditions

Hidradenitis Suppurativa

Interventions

Ruxolitinib 1.5% Cream

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)
  “PI and Sponsor decided to not proceed with the trial.” (78% match in meaning)
• Comparison of Quadratus Lumborum Block Types
  “PI left the institution. Decision made to close the study.” (75% match in meaning)
• Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas
  “The PI is leaving the institution and the trial will be not resuming.” (74% match in meaning)
• A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
  “Decision was made by Sponsor to stop the trial.” (73% match in meaning)
• Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma
  “PI relocated and reopened trial in new university” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.